Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease

Huang, Khan, Au, Barber, López-Vásquez, Prokopishyn, Boutin, Rothe, Rip, Abaoui, Nagree, Dworski, Schambach, Keating, West, Klassen, Turner, Sirrs, Rupar, Auray-Blais, Foley, Medin. Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease. Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017. doi:  10.1016/j.omtm.2017.05.003

Read More

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine Conjugated Antibody–Drug Conjugate Targeting 5T4

Harper, Lloyd, Dimasi, Toader, Marwood, Lewis, Bannister, Jovanovic, Fleming, d’Hooge, Mao, Marrero, Korade, Strout, Xu, Chen, Wetzel, Breen, van Vlerken-Ysla, Jalla, Rebelatto, Zhong, Hurt, Hinrichs, Huang, Howard, Tice, Hollingsworth, Herbst, Kamal. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine Conjugated Antibody–Drug Conjugate Targeting 5T4. Mol Cancer Ther; 16(8) August 2017. DOI: 10.1158/1535-7163.MCT-16-0825

Read More